ATE202940T1 - Mittel und methoden zur behandlung von plaque- krankheiten - Google Patents
Mittel und methoden zur behandlung von plaque- krankheitenInfo
- Publication number
- ATE202940T1 ATE202940T1 AT95921438T AT95921438T ATE202940T1 AT E202940 T1 ATE202940 T1 AT E202940T1 AT 95921438 T AT95921438 T AT 95921438T AT 95921438 T AT95921438 T AT 95921438T AT E202940 T1 ATE202940 T1 AT E202940T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- treating plaque
- plaque diseases
- disease
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24917594A | 1994-05-25 | 1994-05-25 | |
PCT/US1995/006689 WO1995031996A1 (en) | 1994-05-25 | 1995-05-25 | Materials and methods for treatment of plaquing diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE202940T1 true ATE202940T1 (de) | 2001-07-15 |
Family
ID=22942344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95921438T ATE202940T1 (de) | 1994-05-25 | 1995-05-25 | Mittel und methoden zur behandlung von plaque- krankheiten |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0760676B1 (de) |
JP (1) | JP3064013B2 (de) |
AT (1) | ATE202940T1 (de) |
AU (1) | AU686818B2 (de) |
CA (1) | CA2191101C (de) |
DE (1) | DE69521700T2 (de) |
WO (1) | WO1995031996A1 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174916B1 (en) | 1990-04-27 | 2001-01-16 | Milkhaus Laboratory, Ltd. | Methods for treating herpes virus infections |
US5753624A (en) * | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
US5877198A (en) * | 1996-10-17 | 1999-03-02 | Milkhaus Laboratory, Inc. | Treatment of urinary incontinence |
US6156780A (en) * | 1996-10-17 | 2000-12-05 | Milkhaus Laboratory, Inc. | Treatment of fecal incontinence |
US5798102A (en) * | 1997-03-04 | 1998-08-25 | Milkhaus Laboratory, Inc. | Treatment of cardiomyopathy |
US6303127B1 (en) | 1997-03-04 | 2001-10-16 | Milkhaus Laboratory, Inc. | Treatment of disease states |
AU2006202899B2 (en) * | 1997-12-02 | 2009-10-29 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidogenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
EP1033998B1 (de) * | 1997-12-03 | 2005-10-19 | Neuralab, Ltd. | Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US7060670B1 (en) | 1999-05-05 | 2006-06-13 | Neurochem (International) Limited | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
WO2001077167A2 (en) * | 2000-04-05 | 2001-10-18 | University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
DE60108111T2 (de) * | 2000-05-22 | 2005-12-08 | New York University | Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate |
JP2003516929A (ja) * | 2000-06-01 | 2003-05-20 | ニユーララブ・リミテツド | アミロイド形成性疾患の予防および治療 |
CA2414772C (en) * | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
EP1572894B1 (de) | 2001-11-21 | 2016-04-13 | New York University | Zu amyloid-beta, prionprotein, amylin, alpha-synuclein oder polyglutaminwiederholungen homologe synthetische immunogene, jedoch keine ablagerungen bildende polypeptide und peptide zur induzierung einer immunreaktion dagegen |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
JP4703400B2 (ja) * | 2005-12-28 | 2011-06-15 | 三洋電機株式会社 | 固体電解コンデンサ及びその製造方法 |
RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
DK2182983T3 (da) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
CN102858352B (zh) | 2010-04-28 | 2015-05-06 | 爱尔康研究有限公司 | 含有鏻抗微生物剂的药物组合物 |
US8906382B2 (en) | 2011-07-19 | 2014-12-09 | New York University | Method for treating amyloid disease |
US9926353B2 (en) | 2011-07-19 | 2018-03-27 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
JP2012102131A (ja) * | 2012-01-05 | 2012-05-31 | Elan Pharma Internatl Ltd | アミロイド形成性疾患の予防および治療 |
KR20230129449A (ko) | 2014-07-10 | 2023-09-08 | 바이오악틱 에이비 | 개선된 Aβ 프로토피브릴 결합 항체 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE153534T1 (de) * | 1990-04-27 | 1997-06-15 | John Mcmichael | Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein |
-
1995
- 1995-05-25 WO PCT/US1995/006689 patent/WO1995031996A1/en active IP Right Grant
- 1995-05-25 AT AT95921438T patent/ATE202940T1/de not_active IP Right Cessation
- 1995-05-25 DE DE69521700T patent/DE69521700T2/de not_active Expired - Fee Related
- 1995-05-25 JP JP7530548A patent/JP3064013B2/ja not_active Expired - Fee Related
- 1995-05-25 EP EP95921438A patent/EP0760676B1/de not_active Expired - Lifetime
- 1995-05-25 CA CA002191101A patent/CA2191101C/en not_active Expired - Fee Related
- 1995-05-25 AU AU26519/95A patent/AU686818B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CA2191101A1 (en) | 1995-11-30 |
WO1995031996A1 (en) | 1995-11-30 |
AU686818B2 (en) | 1998-02-12 |
JP3064013B2 (ja) | 2000-07-12 |
DE69521700T2 (de) | 2001-10-25 |
JPH09510732A (ja) | 1997-10-28 |
DE69521700D1 (de) | 2001-08-16 |
AU2651995A (en) | 1995-12-18 |
CA2191101C (en) | 2001-08-07 |
EP0760676B1 (de) | 2001-07-11 |
EP0760676A1 (de) | 1997-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE202940T1 (de) | Mittel und methoden zur behandlung von plaque- krankheiten | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
YU46097A (sh) | Nova klasa estara i njihove farmaceutske smeše | |
ATE153534T1 (de) | Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein | |
TR200002773T2 (tr) | Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı. | |
ATE211129T1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
DE69533040D1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
DE69733132D1 (de) | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen | |
DE69536017D1 (de) | Methoden und zusammensetzungen für die behandlung von glomerulonephritis | |
ATE296634T1 (de) | (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
DE69521620T2 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
PT865294E (pt) | Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob | |
DE69706566T2 (de) | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit | |
ATE411026T1 (de) | Mittel zur behandlung der alzheimer-krankheit | |
ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
DE69805305D1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
ATE213163T1 (de) | Verfahren zur behandlung von motorischen defiziten | |
DE59900222D1 (de) | Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
DE69621786D1 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
DE69900774T2 (de) | Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |